Journalartikel

Jahr der Veröffentlichung: 2004

Seiten: 359-370

Zeitschrift: Clinical Chemistry and Laboratory Medicine

Bandnummer: 42

Heftnummer: 4

ISSN: 1434-6621

eISSN: 1437-4331

DOI Link: https://doi.org/10.1515/CCLM.2004.065

Verlag: De Gruyter

Abstract: 
Recurrent pregnancy loss has been associated with autoimmune responses to membrane phospholipids and alloimmune reactions against paternally derived molecules on the trophoblast. The problem is psychologically and economically stressful as it undermines the capacity of some couples to reproduce and participate effectively in the daytoday economic activities. This article reviews the adoption of intravenous immunoglobulin as a form of therapy for the clinical management of recurrent pregnancy loss and of selected autoimmune disorders. Side effects, contraindications and safety of use are discussed.

Harvard-Zitierstil: Omwandho, C., Gruessner, S., Roberts, T. and Tinneberg, H. (2004) Intravenous immunoglobulin (IVIG): modes of action in the clinical management of recurrent pregnancy loss (RPL) and selected autoimmune disorders, Clinical Chemistry and Laboratory Medicine, 42(4), pp. 359-370. https://doi.org/10.1515/CCLM.2004.065

APA-Zitierstil: Omwandho, C., Gruessner, S., Roberts, T., & Tinneberg, H. (2004). Intravenous immunoglobulin (IVIG): modes of action in the clinical management of recurrent pregnancy loss (RPL) and selected autoimmune disorders. Clinical Chemistry and Laboratory Medicine. 42(4), 359-370. https://doi.org/10.1515/CCLM.2004.065